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Introduction 
Tuberculosis (TB) is a major public-health problem 
with around 9 million new cases and 2 million deaths 
estimated to occur each year. 1 About one-third of  the 
world’s population has latent TB with a lifetime risk 
of  TB disease of  10%.2 However, among those co-
infected with HIV and latent TB infection, the risk for 
TB reactivation is 10% per year.3 About 20% of  TB 
is extra-pulmonary disease.4 Tuberculous meningitis is 
the most severe form of  extra pulmonary tuberculosis. 
Its exact incidence and prevalence are not known in 
resource poor countries but in developed countries it 
ranges between 0 and 1 per 100,000 population.5 In 
South Africa, the incidence of  TBM in Western Cape
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province was 24 per 100,000 population among children 
aged 0 to 4 years for the period of  1985-1987.6 The high 
prevalence of  HIV and TB in this region led to a rise 
in TBM.7,8 In the Western Cape province, TBM was the 
leading cause of  meningitis among children below 13 
years of  age.7
Diagnosis of  TBM is complicated because of  its non 
specific clinical presentation which may be acute, sub 
acute or chronic. It may be febrile or afebrile. The 
signs and symptoms of  stage 1 TBM disease are non 
specific and relate more to primary lung infection 
than neurological disease.5 TBM mainly affects young 
children with the mean age ranging between 23 and 
49 months.9,10,11 Diagnosis requires a high index of  
suspicion from the clinician. The Mantoux test is 
positive in only 30 to 50% and chest X-ray is normal in 
20-50% of  cases.10,11 Although radiological tests such as 
brain Computed Tomography (CT) scan or Magnetic 
Resonance Imaging (MRI) are helpful, they may be 
normal in early stages and are not widely available in 
resource limited settings. Lumbar cerebrospinal fluid 
(CSF) is the most valuable test. The CSF proteins 
are elevated and may be markedly raised to 0.4 g/L 
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Abstract
Background: Diagnosis of  tuberculous meningitis (TBM) is complicated and outcome is poor especially in resource limited 
settings. Early diagnosis and prompt treatment are vital in effective treatment. We set out to describe experiences in the 
management and immediate outcome of  TBM a tertiary-level children’s hospital in a high HIV and tuberculosis co-infection 
setting.
Methods:This retrospective study included children who were diagnosed with TBM in the year 2009. A pre-coded 
questionnaire was used to extract data on presentation, diagnostics, treatment and outcome at the time of  hospital discharge. 
Data was analyzed using STATA statistical package (StataCorp, Version 11).
Results: Of  the 40 children diagnosed with TBM, 6 (15%) had definitive TBM, 17 (42.5%) had
probable TBM and 17 (42.5%) had possible TBM. The cerebrospinal fluid (CSF) chemistry and cells were abnormal in 39/40 
(98%). Mantoux test was reactive in 16/29 (55%) and 17/30 (57%) had Chest X-rays suggestive of  tuberculosis. Only 3/21 
(14%) had positive sputum tuberculosis culture and 89% (32/36) had neuro-imaging abnormalities. Outcome at discharge 
was; 8% died, 49% improved with neurological sequelae and 43% improved without sequelae. Having TBM stage 3 at 
admission was associated with mortality (p=0.001).
Conclusions: Most children had early diagnosis of  TBM and mortality was lower than in previous studies.  We recommend 
a larger prospective study to further understand the outcome of  TBM.  
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to 5.0g/L secondary to hydrocephalus and spinal 
block. However, ventricular CSF may record normal 
chemistry and cells if  drawn from a site proximal to 
the inflammation and obstruction. Leukocytes in CSF 
are increased to 10-500 cells/mm3, with majority having 
lymphocyte predominance. However, neutrophils may 
predominate initially which can confuse the picture. 
The gold standard in diagnosis of  TBM is positive 
culture of  Mycobacteria tuberculosis from CSF which has 
both a long turn around time and a low smear and 
mycobacteria culture positive rate except if  10 to 20ml 
of  CSF are supplied to the laboratory.12 Newer tests 
like the GeneXpert with a quick turn around time have 
been found to have a high sensitivity on sputum even in 
children.13 However, studies show a reduced sensitivity 
of  GeneXpert in CSF compared to sputum.14 
Other tests that would support TBM diagnosis like 
sputum or gastric aspirates also have low culture yields.5 
To standardize diagnosis, a consensus case definition 
using clinical presentation, laboratory and radiological 
findings was made to guide clinicians and researchers.15 
Outcome of  TBM is generally poor with mortality 
among children ranging between 13-69%.9,16,17  Younger 
age, tonic posturing, papilloedema, focal neurological 
deficit and stage at presentation were found to affect 
the prognosis.16,17 
Red Cross War memorial Children’s Hospital 
(RCWMCH) is a high TB and HIV burden setting 
with the prevalence of  HIV and TB of  27.6% and 
16.7% respectively among admitted patients on general 
paediatric wards.18 With this high prevalence, there 
was a need to document the diagnosis and treatment 
outcome of  TBM in this hospital. We set out to describe 
our experiences in the presentation, diagnostic rigor, 
treatment and outcome of  TBM at discharge from 
RCWMCH in the year 2009.
Methodology
This retrospective study was conducted at RCWMCH, 
a tertiary referral hospital affiliated to the University of  
Cape Town in South Africa. The study was approved 
by the Research ethics Committee of  the University of  
Cape Town. The entry point was the hospital database 
which was used to generate a list of  children who had 
been diagnosed with TBM from 1st January 2009 to 31st 
December 2009. The clinical notes of  these patients 
were reviewed and relevant clinical data relating to the 
presentation, diagnosis, management and outcome of  
the children extracted using a pre-tested, pre-coded 
study tool. 
We obtained the results of  radiological examinations 
such as chest radiographs and brain CT scans or MRIs 
from the patient folders. Laboratory results were 
extracted from the National Health Laboratory Services 
electronic database. These included cerebrospinal fluid 
chemistry, microscopy, mycobacterial culture and 
antibiotic sensitivity, HIV test, sputum microscopy and 
mycobacterial culture results.  The recently published 
consensus case definition of  TBM was used to evaluate 
diagnostic certainty.15 This diagnostic criteria uses the 
clinical presentation and diagnostic tests to categorize 
TBM into Definitive, Probable, Possible and No TBM. 
Those who had a diagnosis of  TBM in the folder 
but did not qualify according to the consensus case 
definition were excluded. Definite TBM was considered 
when Mycobacterium tuberculosis is isolated from CSF. 
Probable and Possible TBM were diagnosed according 
to consensus case definition for TBM for use in future 
clinical research.15 Probable TBM was considered when: 
1) a patient presented with clinical features of  meningitis 
and 2) suggestive CSF findings of  TBM (total white cell 
count >5 cells×106/L, protein >0.45 g/L and glucose 
<2.2 mmol/L), plus 3) one or more of  the following 
i) chest radiograph findings consistent with pulmonary 
TB, ii) an extra-meningeal specimen positive for AFB, iii) 
other evidence of  extra-meningeal TB (e.g. abdominal 
ultrasound features) or iv) brain computed tomography 
(CT) evidence of  TBM including one or more of  the 
following: basal meningeal enhancement, hydrocephalus 
or infarctions. Possible TBM was diagnosed when: 1) a 
patient presented with clinical features of  meningitis and 
either 2) four or more of  the following were present i) a 
history of  TB ii) a predominance of  CSF lymphocytes 
(>50%), iii) illness duration of  more than five days iv) 
CSF glucose <2.2 mmol/L, v) altered consciousness, 
vi) clear or yellow CSF with protein>1 g/L, vii) focal 
neurological signs, or 3) ‘markedly abnormal’ CSF 
(excluding isolated hypoglycemia) with evidence of  TB 
elsewhere.
For children who were transferred to other hospitals in 
Cape Town to complete their treatment, those hospitals 
were visited and their treatment outcomes at discharge 
recorded. The outcome of  treatment variables were 
improvement with / without neurological sequelae, 
or death. Poor outcome was defined as death or 
neurological sequelae at discharge.  The neurological 
sequelae were obtained from the doctors’ notes and it 
included physical neurological sequelae. 
The Mantoux skin test is regarded as reactive as defined 
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by guidelines of  the World Health Organization: in 
high risk children (including HIV-infected children and 
severely malnourished children), >5 mm of  induration, 
and in all other children (whether they have received a 
BCG vaccination or not), >10 mm of  induration.19
TBM staging was undertaken using the modified 
criteria of  the British Medical Research Council: 20 in 
which TBM Stage I is defined as (Glasgow Coma Scale 
(GCS) 15 with no focal neurologic signs), TBM stage 
II is (GCS 11–14 or GCS of  15 with focal neurologic 
deficit) and TBM stage III is (GCS <11). 
Statistical Analysis 
Data was entered anonymously into an excel spreadsheet. 
To assess the accuracy of  the data entered, a random 
sample of  the original forms was compared with a 
computer print-out. Data was analyzed using STATA 
statistical package (StataCorp, Version 11). Descriptive 
analysis using medians with inter-quartile ranges 
(IQR) are described for continuous variables that are 
not normally distributed while means and standard 
deviations (SD) are used for normally distributed data. 
For categorical variables, proportions are depicted as 
percentages of  cases for which data is available. Data 
were tested for normality and the appropriate statistical 
test was used to test for strength of  association. 
Results
Of  22,943 children admitted to RCWMCH during the 
study period, we identified 40 children newly diagnosed 
with TBM; an incidence rate of  1.7 per 1000 admissions. 
The median age was 32 months (IQR 9-78.5) ranging 
from 6 weeks to 12 years. The male: female ratio was 1:1. 
Clinical features present at admission are summarized 
in table 1. 
Table 1: Clinical features at presentation
Presentation Frequency* Percentage
History of  Fever 25/30 83%
Temperature above 37.50C 14/38 37%
Altered level of  consciousness 23/32 72%
Convulsions 12/16 75%
Irritability 11/13 85%
Poor feeding 17/20 85%




Difficulty in breathing 7/26 26%
Failure to thrive 22/25 88%
Meningism 23/30 77%
Bulging fontanelle 4/8 50%
Neurological deficits 21/34 62%
Admission Fever Duration       1-7 days 14 74%
(N=19)                                    7-10 days 5 26%
*The denominator varies according to available data. #Only those above 4 years
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Common features included fever, vomiting, meningism, 
neurological deficits, altered level of  consciousness and 
failure to thrive. Although 25/30 (83%) had a history 
of  fever, 14/38 (37%) had a temperature of  37.50C and 
above, one had 34.50C and 23/38 (61%) had a normal 
temperature between 35 and 37.40C at admission.  Of  
the 32 with data on level of  consciousness, only 18 had 
a record on the Glasgow coma scale. Of  these 18, 9 had 
TBM stage 2 and 9 had TBM stage 3 according to the 
British Medical Research Council.20 
According to the consensus case definition of  TBM12, 6 
(15%) had definitive TBM, 17 (42%), probable TBM and 
18 (44%) possible TBM.  Thirty-five patients (87%) were 
screened for HIV, of  whom only 3 (10%) were infected. 
No patients were receiving antiretroviral therapy (ART) 
at the time of  TBM diagnosis. In addition, two were HIV 
exposed but their HIV DNA/PCR test was negative. 
Only 20/40 had available records on immunization and 
they all had received BCG vaccination. 
Table 2 summarizes the CSF results. 
          145
Table 2: Cerebrospinal Fluid Findings
Results Frequency* Percentage
CSF TB culture positive# 6/22 27%
AAFBs negative# 22/22 100%
Raised proteins concentration 
>0.4g/l
35/38 92%
Increased cell count >5cells/mm3 38/39 97%
Lymphocyte predominance 32/39 82%
Neutrophil predominance 7/39 18%
*The denominator varies according to available data, # Only 22 had CSF culture and AAFB
The CSF protein concentration results were available 
in only 38 out of  40 children.  Of  these, 92% had 
raised protein concentration in CSF above 0.4g/l but 
23 (62%) had markedly raised proteins above 1.0g/l. 
Ninety seven percent had above 5 cells /mm3 as shown 
in table 2 below. Cells were predominantly lymphocytes 
in 33 (83%). There were no results of  blood glucose, 
but 33/38 (87%) had CSF glucose below 3.0 mmol/l. 
Other tests done to make a diagnosis of  tuberculosis 
including Mantoux test, chest X-rays, sputum smear 
and culture, and CT and MRI are summarized in table 
3 below.
Of  the 30 who had data on chest X-ray findings, abnormal 
findings were present in 24 (71%).  Seventeen (57%) 
had findings suggestive of  TB which included 5 (29%) 
with hilar or mediastinal lymphadenopathy, 4 (24%) 
with miliary picture, 4 (24%) with hilar adenopathy and 
reticulonodular infiltrates, 2 (12%) with lobar infiltrates, 
1 (6%) with consolidation and perihilar infiltrates and 1 
(6%) with consolidation and fine nodular opacities like 
miliary. Other abnormal chest X-ray findings included 
3 with isolated right upper lobe consolidation, 3 with 
peri-hilar and hilar infiltrates and pneumonia and 1 with 
bronco pneumonic picture.
Neuroimaging tests revealed that 33/36 (92%) had an 
abnormality on CT or MRI as shown on table 3. 
Table 3: Results of  other TB investigations 
Investigation Frequency* Percentage
Mantoux test  reactive 16/28 57%
Chest X-ray suggestive of  TB. 17/30 57%
TB sputum culture positive. 3/21 14%
TB sputum smear negative 21/21 100%
CT/MRI results
Basal meningeal enhancement 18/36 50%
Hydrocephalus 16/36 44%
Cerebral infarcts 12/36 33%
Cerebral oedema  11/36 31%
Normal 4/36 11%
*The denominator varies according to available data
The commonest finding was basal meningeal 
enhancement which was present in 50% but 25/33 (76%) 
had multiple abnormalities; 12 had 2 abnormalities, 9 
had 3 abnormalities and 4 had 4 abnormalities.
 
Management and Outcome:
All the children were treated with oral rifampicin, 
isoniazid, pyrazinamide and ethionamide which is the 
standard treatment in the country.21 They all received 
glucocorticosteroids; 36 (90%) received Prednisolone 
and 4/40 (10%) received Dexamethazone. Mannitol 
was administered to 6/40 (15%). TB treatment was 
started on day 1 of  admission in 25/37(67.5%), day 2 
in 5/37 (13.5%) and day 3 in 7/37 (19%). Three of  the 
patients had no clear records about the date of  initiation 
of  TB treatment. Surgery was performed on 10/40 
(25%) – an extraventricular drain (EVD) alone was 
inserted in 3 children, 6 children received a ventriculo-
peritoneal (VP) shunt alone and 1 child had both EVD 
and VP shunt.  Six (15%) children with communicating 
hydrocephalus received serial lumbar punctures to 
reverse raised intracranial pressure. All 6 children had 
poor outcome. 
Children with poor outcome of  death and neurological 
sequelae had a statistically longer hospital stay with a 
median of  30 days, IQR 16-40 days while those with 
good outcome had a median of   5 days, IQR 2-17 days 
(Mann Whitney p<0.001). From RCWMCH, 2 went 
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home, 2 died and 36 were referred to another hospital 
to complete their treatment. Of  this latter group, 21 
were admitted to the local TB hospital, Brooklyn Chest 
Hospital and 15 admitted to general hospitals in Cape 
The outcome of  4 children could not be established 
because they were transferred to other hospitals too early 
and we did not find the data on outcome at discharge. 
The trends noted with poor outcome were having 
surgery; (8 versus 1), serial LPs, (6 versus none), 
acetazolamine use (7 versus none) and longer mean 
hospital stay. There was a strong association between 
poor outcome (death and neurological sequale) and 
TBM stage 3 on admission, Fischer’s exact test p<0.01. 
There was no association found between poor outcome 
and other presentations on admission. These included 
HIV status, CSF white cell count, age, CSF chemistry 
(protein and glucose), microscopy and culture.
The neurological sequelae experienced by the 18 
children included hydrocephalus, (11), motor deficits 
(11), cranial nerve palsies (9), deafness (2), epilepsy (1), 
cortical blindness (1). Twelve of  them suffered multiple 
sequelae.
Discussion
TBM is a severe disease whose initial presentation in 
children is like other common childhood illnesses 
resulting in late diagnosis. Although it is usually 
associated with poor outcome, our study found better 
treatment outcome and several lessons that can be 
drawn and applied.
We found a mean age of  48 months and only 11 were 
infants under 1 year. This is comparable to what several 
studies indicate that TBM mainly affects young children 
with the mean age ranging between 23 and 49 months.9-
11 All the 20 children with immunization records had 
BCG vaccine which is not surprising because although 
BCG is protective against TBM, studies show that those 
who get TBM after vaccination have a better treatment 
outcome.22  
RCWMCH has a high HIV prevalence of  27.6% on 
general paediatric wards but it was surprisingly low 
at 9.7% among those with TBM. Previous studies 
showed that HIV is a risk factor for central nervous 
system TB.3,5,7,8,23 However, Gijs et al also found a low 
HIV prevalence of  3.8% among children with TBM in 
Western cape province.9 This could be explained by the 
high burden of  TB in the region such that children are 
infected regardless of  their HIV status.
We found that TBM in these children presented mainly 
with non specific common childhood diseases but 
the data on duration was generally deficient. Of  the 
19 who had duration of  fever, all were affected for 
less than 10 days. Cough was acute in 8/15 (53%) of  
children. Several studies have similar findings of  short 
duration of  symptoms.5,8-10 More severe symptoms like 
convulsions and impaired level of  consciousness were 
present in 12/16 (75%)% and 23/32 (72%) respectively. 
These percentages seem high because many did not 
have records and it can be hypothesized that the ones 
without records most likely did not have the symptoms. 
Paradoxically, failure to thrive was present among 22/25 
(88%) despite the short duration of  symptoms in the 
majority. This is similar to Gitz et al’s study.9 We could 
not determine missed opportunities of  early treatment 
because of  the retrospective design. This has been 
described by other studies.5, 9
Despite the difficulties of  diagnosis of  TBM, our study 
demonstrated that almost all had a diagnosis made by 
day 3 of  admission. This is because of  the high index 
of  suspicion and also the hospital had access to quick 
laboratory and radiological tests which helped make a 
quick diagnosis and also start treatment early. 
Definite TBM was present in only 15% (Mycobacterium 
tuberculosis isolated from CSF).15 TB culture positive 
rates in CSF were lower in this study because only one 
sample was used. Daniel et al found that culture positive 
rates can go up from 53% on the first specimen to 83% 
with the third specimen.24
Outcome of  treatment
Of  the 36 children with available treatment outcome 
at discharge from hospital, 15/36, (42%) improved 
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Town.
Table 4 summarizes the outcome at final hospital 
discharge. 
Table 4: Treatment Outcome
 Outcome Frequency Percentage
 Improved without neurological sequelae. 15/36 42%
 Improved with neurological sequelae 18/36 50%
 Died  3/36 8%
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without neurological sequelae, 18/36, (50%) improved 
with neurological sequelae and 3/36, (8%) died. 
Our results were different from Gitz et al in another 
retrospective study on the outcome of  paediatric TBM 
after 6 months of  treatment which was conducted 
between January 1985 and April 2005 in South Africa. In 
their study, the clinical outcome of  the 554 patients was 
as follows: normal (16%), mild sequelae (52%), severe 
sequelae (19%), and death (13%).9 Unfortunately, we did 
not grade the neurological sequelae due to the deficient 
data in our retrospective study. Outcome would also be 
different at the end of  treatment compared to the time 
of  hospital discharge when the neurological outcome is 
still evolving. The mortality in our study was 8% which 
is much lower than has been described in other studies 
where mortality ranges between 13% and 69% even in 
developed countries.8-10,25-28 The better outcome in this 
study may be because all the 37 with records on date of  
starting antiTB treatment (ATT) had started treatment 
within 3 days of  admission. Early initiation of  treatment 
has been established as the main prognostic factor that 
predicts disease lethality and sequelae.29-30  In addition, 
only 9 had TBM stage III basing on the GCS although 
23 had impaired level of  consciousness at admission. 
Stage III is associated with worse outcome.9,16,17 
Availability of  radiological tests like CT and MRI which 
were performed in 36/40 (90%) and were abnormal in 
89% of  cases further strengthened the diagnosis and 
then early treatment. Since TB prevalence is high in 
this region, TBM is always held in high suspicion and 
treatment was started early with good results.
In addition, the prevalence of  HIV was low in the study. 
HIV was not associated with poor outcome probably 
because the numbers were very few. HIV co-infection 
has been associated with poor treatment outcome of  
TBM in children.9 
Like in other studies, we found that TBM stage III was 
associated with increased mortality.9,16,17 Our study was 
not powered to look for associations but those who 
had surgery, serial LPs, acetazolamine use and longer 
mean hospital stay had poor outcome of  death and 
neurological sequelae. Similarly, longer hospital stay has 
been associated with poor outcome.31 Misra et al also 
found that hydrocephalus and shunt surgery were poor 
prognostic features.17
The strength of  this descriptive study is that we used a 
retrospective chart review to attain
data on a disease known to have very poor outcome and 
found better outcome than other studies. Our findings 
suggest that it is possible to reduce mortality and to 
improve outcome from TBM with rigorous diagnostics 
and early treatment initiation.
Limitations of  our study included the retrospective 
design in which data recording was not standardized 
and as such some information was missing. In addition, 
we used the neurological sequelae recorded by the 
doctors in the folders which had missing data and could 
not therefore grade it. Another limitation was with our 
entry point which was the hospital records department. 
Some TBM diagnoses may have been missed out just as 
we found that some codes were in error.
Conclusions 
We found that TBM mainly presented with acute non 
specific symptoms but the rigorous diagnostics helped 
make a quick diagnosis and start early treatment. 
Outcome of  treatment at discharge was good with less 
than 10% mortality and half  with neurological sequelae 
at discharge from hospital. Poor outcome was associated 
with TBM stage III disease.
Recommendations
We recommend a prospective study on the same topic 
so that the sequelae can be well documented. Since 
the presentation of  TBM is non specific, clinicians in 
high TB endemic regions should have a high index 
of  suspicion among all children with or without HIV 
infection. On suspicion of  TBM, TB treatment should 
be started in the first 2 days of  admission to improve 
the outcome.
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